DiagnoCure and Genzyme seal lung cancer test pact
This article was originally published in Clinica
In a bid to optimise its investigational molecular test for lung cancer, DiagnoCure has licensed from Genzyme worldwide exclusive rights to around 40 genes for potential use in detecting the disease. The genes are intended to supplement those in the original version of DiagnoCure's assay - which uses bronchial aspirate samples - and may also be used to develop new tests that employ other sample types such as blood, sputum, or biopsy materials.
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.